Trifluridine/tipiracil with or without bevacizumab in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: A retrospective observational study
Published in
Therapeutic Advances in Medical Oncology, August 2026
Practitioners (doctors, other healthcare professionals)
3
23%
Scientists
3
23%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 August 2026.
All research outputs
#7,571,202
of 34,344,438 outputs
Outputs from Therapeutic Advances in Medical Oncology
#317
of 1,235 outputs
Outputs of similar age
#44,898
of 297,224 outputs
Outputs of similar age from Therapeutic Advances in Medical Oncology
#2
of 29 outputs
Altmetric has tracked 34,344,438 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 1,235 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 297,224 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.
